Group 1 - The company, Watson Bio, stated on October 24 that it will disclose any substantial and phase-related progress in the research and registration of its vaccines in a timely manner [2]

Core Viewpoint - Jiangsu Zhonghui Yuantong Biotechnology Co., Ltd. (stock code "Zhonghui Bio", 02627.HK) has experienced a significant decline in its stock price, closing at 44.88 HKD on its fourth trading day, reflecting a drop of 14.02% from its initial offering price [1] Summary by Categories Company Overview - Zhonghui Bio's global offering included a total of 33,442,600 H shares, with 3,996,000 shares allocated for the Hong Kong offering and 29,446,600 shares for international offering [1] Financial Performance - The final offering price was set at 12.90 HKD per share, resulting in total proceeds of 431.4 million HKD. After deducting estimated listing expenses of 48.7 million HKD, the net proceeds amounted to 382.7 million HKD [1] Use of Proceeds - The net proceeds from the global offering will be allocated as follows: approximately 63.6% for the development and registration of core products; about 18.1% for the development and registration of other vaccines in research; around 8.4% for improving processes and commercialization capabilities; approximately 4.9% for the development of technology platforms; and about 5.0% for working capital and other general corporate purposes [1]

Group 1 - The core stock of Zhonghui Biotech surged over 12% to HKD 37.5 after its initial public offering (IPO), which saw a remarkable increase of 158% on the first day of trading [2][3] - The stock opened at HKD 34.0, with a trading volume of 775,600 shares and a total transaction value of approximately HKD 27.72 million [3] - The company's total market capitalization reached HKD 14.754 billion, with a total share count of 393 million [3] Group 2 - Zhonghui Biotech issued a total of 33.4426 million H-shares at an offering price of HKD 12.90, which was at the lower end of the pricing range, raising approximately HKD 431 million [4] - The funds raised from the IPO will primarily be used for the development and registration of its core products, as well as for the development and registration of other vaccines in the pipeline, and to enhance its manufacturing processes and commercialization capabilities [4]